Skip to content

Impact of Helminth Infections During Pregnancy on Humoral Vaccine Immunogenicity in Infants

Impact of Helminth Infections During Pregnancy on Humoral Vaccine Immunogenicity in Infants

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02714348
Enrollment
323
Registered
2016-03-21
Start date
2014-02-28
Completion date
2016-09-30
Last updated
2016-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maternal Infection Affecting Newborn

Keywords

Helminth infection, Vaccination

Brief summary

Helminth infection is associated with low vaccine immunogenicity. Pregnant women are particularly sensitive to helminth infection. Since most vaccines are given shortly after birth, an effect of parasites on infant immunogenicity is of particular concern. Therefore, within this study the investigators aim to investigate if maternal infection influences vaccine immunogenicity in the newborn.

Detailed description

There is evidence that helminth infections during pregnancy affect the immune system of the mother and the unborn child. As a consequence, the antimicrobial- immune and vaccine- response of the infant may be deficient. The aim of the present study is to measure the influence of maternal helminth infection (schistosomal, filarial and intestinal helminth infection) on vaccine immunogenicity of their infants. The main focus is on immune responses of infants to vaccine antigens given as part of the expanded program on immunization (EPI) in Gabon at an age when infants are unlikely to be infected with helminths and are immunologically primed by their intrauterine life. The objective is to investigate if and which species of helminths during pregnancy have an effect on any of the EPI vaccine-induced immune responses.

Interventions

OTHEREffect of helminth infection on vaccine immunogenicity

Observational; immunology

Sponsors

University Hospital Tuebingen
CollaboratorOTHER
Centre de Recherche Médicale de Lambaréné
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Signed informed consent form (ICF) by the participant aged 18 years or older or by a legal major representative and the participant * Willingness to deliver in one of the two maternities in the study area * Willingness and ability to comply with study protocol for the duration of the trial * Willingness to give blood for the examinations and to provide samples for helminth assessment (stool, urine, blood)

Exclusion criteria

* Known chronic diseases (diabetes, TB, HIV, HCV or HBV infection); these will be assessed on a regular basis at given examinations during pregnancy * Withdrawal of consent * Poor general health (including a hemoglobin level out of local reference range) * Signs of symptoms of helminth infection which needs immediate treatment of the mother * Planned migration from the area

Design outcomes

Primary

MeasureTime frame
Difference in Immunoglobulin G (IgG) concentration against EPI vaccine Ags of infants born to helminth infected mothers and non infected mothers at the age of nine months and 12 months12 months of observation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026